What Analysts Are Saying About Axsome Therapeutics Stock
Portfolio Pulse from Benzinga Insights
Axsome Therapeutics (NASDAQ:AXSM) has been analyzed by 17 analysts, showing a range of opinions from bullish to bearish. The average 12-month price target is $129.06, with a high of $180.00 and a low of $95.00. Recent ratings show a mix of 'Maintain', 'Raise', and 'Lower' actions, reflecting dynamic market conditions. Axsome's revenue growth is strong, but profitability metrics like net margin and ROE are below industry averages.
September 09, 2024 | 4:01 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Axsome Therapeutics has received mixed analyst ratings, with a 12-month price target average of $129.06. The company shows strong revenue growth but faces challenges in profitability metrics.
The analysis shows a range of analyst opinions, with a slight increase in the average price target. The company's strong revenue growth is a positive indicator, but challenges in profitability metrics like net margin and ROE may offset this in the short term. The mixed ratings and financial metrics suggest a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100